July 10 , 2008

CONTACT: John Ascenzi
The Children's Hospital of Philadelphia
(267) 426-6055
Ascenzi@email.chop.edu


Novel Approach May Protect Against Heart Attack Injury

Drugs Target Gene Pathways to Preserve Heart, Possibly Other Organs

PHILADELPHIA - Researchers at The Children’s Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since already existing drugs might be pressed into service to produce the protective effects.

“Reduced blood flow, or ischemia, is a major problem in many organs, where it can lead to cell death and tissue damage,” said study leader Peter J. Gruber, M.D., Ph.D., a cardiothoracic surgeon at Children’s Hospital and a faculty member of the University of Pennsylvania School of Medicine. “We decided to look for a global approach to protecting heart tissue by inhibiting enzymes that govern how cells respond to ischemia.”

Gruber’s team published their findings online July 7 in the journal of the Federation of American Societies for Experimental Biology (FASEB). The article will appear in the journal’s October 2008 print issue.

The researchers made use of drugs called histone deactylase (HDAC) inhibitors that alter the way DNA is packaged within cells, as well as modifying the function of other proteins. Building on previous work by other researchers, who showed that HDAC inhibitors reduce ischemic injury in the brain, they used the same agents in mice with induced heart damage.

“We found significant and dramatic results in the mice,” said Gruber. “The HDAC inhibitors reduced the area of tissue injury, even when delivered an hour after the ischemic event occurred.”  The size of the myocardial infarction—an area of dead tissue caused by obstructed blood flow, as occurs after a heart attack—was reduced by more than half.

In further investigating how the HDAC inhibitors acted, Gruber’s team found they blocked gene pathways that led to cell death and ischemia-induced vascular permeability, the leakage of fluid through blood vessels. They also identified a specific molecule, HDAC4, as the likely HDAC enzyme with the most critical role in affecting how cells respond to ischemia.

An important advantage of their finding, said Gruber, is that a number of HDAC inhibitors are already used in medicine, for treating both cancer and epilepsy, and are well-tolerated. Although much research remains to be done, he added, this raises the possibility that existing drugs, or modified versions of them, might play an important new role in heart disease.

Because the protective effect of HDAC inhibitors may occur even after the initial blockage of blood flow, therapies based on Gruber’s research may lead to an emergency treatment following a heart attack. In addition, because open-heart surgery for both children and adults requires a period in which the heart is stopped, such treatment might also protect tissues from the adverse effects of interrupting blood flow during surgery.

For now, said Gruber, the next step for his study team will be to test how HDAC inhibitors work in protecting against ischemic injury in larger animals.

A National Institutes of Health grant partially supported the research, in addition to funding from the McCabe Foundation, the University Research Foundation and the Division of Pediatric Cardiothoracic Surgery at The Children’s Hospital of Philadelphia.

Gruber’s co-authors were Anne Granger, Ibrahim Abdullah, Faith Huebner, and Thomas Huebner, of Children’s Hospital; and Jonathan A. Epstein, M.D., of the University of Pennsylvania School of Medicine. Gruber, Granger, and co-authors Andrea Stout and Tao Wang are members of the Penn Cardiovascular Institute, of which Epstein is the scientific director.

###

The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.


This release is available online at
http://www.uphs.upenn.edu/news/News_Releases/2008/07/hdac-heart-attack-protection.html